V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
- 15 December 2010
- journal article
- letter
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 24 (2) , 390-392
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal typeLaboratory Investigation, 2009
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL MutantsJournal of Clinical Oncology, 2009
- Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutationPigment Cell & Melanoma Research, 2008
- Major Response to Imatinib Mesylate in KIT-Mutated MelanomaJournal of Clinical Oncology, 2008
- Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2006
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal of Cancer, 2006
- Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumourThe Lancet Oncology, 2005
- Prevalence of KIT Expression in Human TumorsJournal of Clinical Oncology, 2004
- KIT Mutations Are Common in Testicular SeminomasThe American Journal of Pathology, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003